创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology: iHuPBMC-MHC/KO

  • Categories:Company news
  • Author:InnoModels Biotechnology
  • Origin:InnoModels Biotechnology
  • Time of issue:2024-01-19 14:19
  • Views:

(Summary description)Once again demonstrating a strong commitment to innovation in the biomedical field, InnoModels Biotechnology introduces the iHuPBMC-MHC/KO, an innovative product for immunological research. iHuPBMC-MHC/KO is a forward-thinking product that provides scientists with groundbreaking tools to advance immunological research and expand our understanding of the immune system

InnoModels Biotechnology: iHuPBMC-MHC/KO

(Summary description)Once again demonstrating a strong commitment to innovation in the biomedical field, InnoModels Biotechnology introduces the iHuPBMC-MHC/KO, an innovative product for immunological research. iHuPBMC-MHC/KO is a forward-thinking product that provides scientists with groundbreaking tools to advance immunological research and expand our understanding of the immune system

  • Categories:Company news
  • Author:InnoModels Biotechnology
  • Origin:InnoModels Biotechnology
  • Time of issue:2024-01-19 14:19
  • Views:
Information

Once again demonstrating a strong commitment to innovation in the biomedical field, InnoModels Biotechnology introduces the iHuPBMC-MHC/KO, an innovative product for immunological research. iHuPBMC-MHC/KO is a forward-thinking product that provides scientists with groundbreaking tools to advance immunological research and expand our understanding of the immune system.
Technical Breakthrough of iHuPBMC-MHC/KO
iHuPBMC-MHC/KO is a model based on Human Peripheral Blood Mononuclear Cells (iHuPBMC) with a special focus on Major Histocompatibility Complex (MHC) Knockout (KO). The following are its major technological breakthroughs:
Main Features and Advantages
1. MHC knockout technology:
iHuPBMC-MHC/KO uses advanced gene editing technology to successfully realize MHC gene knockout. This allows researchers to simulate the effects of MHC deletion on the immune system under specific conditions, providing a completely new perspective for immunological research.
2. Research on the mechanism of immune tolerance and rejection:
Modeling provides an ideal platform for studying immune tolerance and rejection mechanisms. Through MHC knockdown, how the immune system responds to the missing MHC can be explored in depth, providing new ideas for organ transplantation and autoimmune disease research.
3. Personalized immunotherapy development:
iHuPBMC-MHC/KO is expected to support the development of personalized immunotherapy. By mimicking different MHC genotypes, researchers can better understand the immune system response to individualized therapies.

 


Scientific applications and future perspectives
1. Immunomodulatory disease therapy:
iHuPBMC-MHC/KO provides a new research tool for the study of immune-modulated disease therapy, which is expected to provide a scientific basis for the design of therapeutic strategies for inflammatory diseases and autoimmune diseases.
2. organ transplantation research:
The model provides unprecedented opportunities for the study of immune rejection in organ transplantation, which is expected to promote innovative development in the field of organ transplantation.
3. Future Innovation Direction:
InnoModels Biotechnology will continue to invest in research and development to explore new areas of immunology and clinical applications of iHuPBMC-MHC/KO, and to promote greater breakthroughs in immunology research.
Conclusion
The launch of iHuPBMC-MHC/KO marks an outstanding innovation in the field of immunology by InnoModels Biotechnology. The unique nature of this product provides scientists with a powerful tool that is expected to drive research progress in the field of immunology and offer more possibilities for future immunotherapy and disease treatment.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司